AMPLY DISCOVERY LIMITED
Company number NI676691 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
£1,650,273
Balance sheet as at 2026-02-28
What it does
The principal activity of the company continued to be that of
The company's own description, from its latest filed accounts.
Overview
- Company type
- Private Limited Company
- Incorporated
- 2021-02-19
- Employees
- 3 (2026 accounts · was 4 in 2025)
- Registered office
- C/O Qubis Ltd, 63 University Road, Belfast, Northern Ireland, BT7 1NF
- Postcode
- BT7 1NF
- Capital
- 147 GBP
- Accounts category
- Micro
Accounts
- Last made up to
- 2026-02-28
- Next due by
- 2027-11-30
- Financial year end
- 28 February
Confirmation statement
- Last statement dated
- 2026-03-06
- Next due by
- 2027-03-20
Nature of business (SIC)
- 72110 Research and experimental development on biotechnology
Officers 5 current
Contact details
- Website
- amplydiscovery.com
AMPLY Discovery is a UK biotech turning the regulatory genome — the part drug developers have largely ignored — into first-in-class RNA medicines for triple-negative breast cancer and high-grade serous ovarian cancer. Six ML engines. Two wet labs. One closed loop between silicon and bench.
Among its peers
Top 10%
by shareholders' funds, of 37 similar companies in BT
Trading since 2021.
No.2 of the largest research and experimental development on biotechnology companies in Belfast →
Competitors Belfast
-
3. PROAXSIS LTD
This company ranks 2 among research and experimental development on biotechnology in Belfast.